| Bioactivity | LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research[1]. | ||||||||||||
| Invitro | In vitro, LGD-6972 binds competitively to glucagon receptor (GCGR) with high affinity and selectivity, suppressing both cAMP and glucose production[1]. | ||||||||||||
| In Vivo | In vivo, LGD-6972 reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models. The pharmacological activity of LGD-6972 appears to be mediated primarily by inhibiting glucagon receptor signaling[1]. | ||||||||||||
| Name | LGD-6972 | ||||||||||||
| CAS | 1207989-09-0 | ||||||||||||
| Formula | C43H46N2O5S | ||||||||||||
| Molar Mass | 702.90 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32. |
LGD-6972
CAS: 1207989-09-0 F: C43H46N2O5S W: 702.90
LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes r
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.